Kanabo Group Plc Share Price London S.E.
Equities
SOP
GB00BYQCS703
Pharmaceuticals
Sales 2021 | 73K 91.19K 7.3M | Sales 2022 | 603K 753K 60.3M | Capitalization | 8.04M 10.04M 804M |
---|---|---|---|---|---|
Net income 2021 | -4M -5M -400M | Net income 2022 | -6M -7.5M -600M | EV / Sales 2021 | 648 x |
Net cash position 2021 | 4.5M 5.62M 450M | Net cash position 2022 | 3.01M 3.76M 301M | EV / Sales 2022 | 8.33 x |
P/E ratio 2021 |
-9.98
x | P/E ratio 2022 |
-1.15
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 50.93% |
Managers | Title | Age | Since |
---|---|---|---|
Avihu Tamir
CEO | Chief Executive Officer | - | - |
Assaf Vardimon
DFI | Director of Finance/CFO | 46 | - |
Ophir Shimshi
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Ian Mattioli
CHM | Chairman | 62 | 08/05/23 |
David Tsur
BRD | Director/Board Member | 73 | 27/06/21 |
Sharon Malka
BRD | Director/Board Member | 51 | 03/05/23 |
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |